Cancer Diagnostics – News and Features

Researchers showed that approximately 80 percent of stage 3 melanoma patients who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence.

Researchers used mutational analysis to identify gene mutations that may drive carcinogenesis in colorectal tumors with high tumor mutation burden.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment.

A research team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumors in chicken eggs and analyzing their proteins.

In this interview, Asim Siddiqui, senior vice president and scientific fellow at Seer, explores the evolving role of unbiased proteomics in cancer research.

Technology Networks spoke to the most productive researcher in spatial transcriptomics, Professor Joakim Lundeberg, about the field’s rapid growth.

Cornell researchers have confirmed that a previously identified biomarker for detecting the presence of malignant testicular germ cell tumors has the potential to improve patient outcomes through early detection, possibly even prenatally.

Researchers from around the UK, led by the University of Oxford, have found that a new way of performing prostate biopsies is better at diagnosing prostate cancer, but takes longer to perform and is more painful for patients.

New research from Mayo Clinic finds that the presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma.

This article explores 6-base genome sequencing and how it is empowering researchers to expand their studies to include both genetic and epigenetic data.